Summit Therapeutics Share Discussion Threads

[luminoso] 01/7/2017 13:25

If the price is right, I would be happy to be swallowed, chewed, and spat out. Especially if it means the drugs getting to market and patients quicker.

[solomon] 30/6/2017 12:58

But we don't want to be swallowed - do we?

[chrisatrdg] 29/6/2017 21:37

Hi All - Very interesting article above & yes the 'New Boy' looks to be a transformative CEO for Sarepta which might influence Summits future.For sure he will be looking at the Summit deal & in turn getting a better understanding of Summits future potential.You never know.

[waterloo01] 29/6/2017 17:40

Umm. Last time we got little warning of the SRPT deal and if there is any sniff of good results.....

"While Schwartz agreed that M&A chatter—particularly surrounding a takeover by deal-frustrated Sanofi—is “likely to re-emerge” with the appointment, he also said Ingram’s track record could “benefit the company’s recent penchant for in-licensing of DMD assets to expand the pipeline.”

[hugus maximus] 28/6/2017 23:07

The American business media seems to like the new Sarepta CEO appointment .. fingers crossed that this bodes well for Summit :

[football] 28/6/2017 10:37

Am I the only one here that gets really peed off when you see 2 Rns's only to open them up and find out it's options news rather than drug test results news



gla

[chrisatrdg] 27/6/2017 20:11

Posted this evening on twitter & posted on Summit Presentations Page:

Slingshot Insights Management Call - 28 June 2017 Listen In



Slingshot members are talking to management! The topic is:
Interviewing the CEO of Summit Therapeutics to discuss the company's leading clinical stage DMD and C Diff programs

[clarkey26] 26/6/2017 22:44

Yep,same issue for a while with Google finance on a number but not all of my UK shares. Seems to still work ok for Nasdaq listing SMMT.

[waterloo01] 26/6/2017 15:10

OT. Does anyone use Google finance to monitor stocks and have on going issues in showing the share price and trades. Mine seems stuck on last week on Summ and a number of stocks. Any ideas?

[hugus maximus] 26/6/2017 09:32

I missed this last week (iii - choice of favourite 4 shares post election)... but am puzzled as to why the share price hasn't started to gain momentum. Perhaps the postponement of data release without rhyme or reason may be responsible? (i.e. RDZ v FDX top line from the tests carried out at the end of the second world war and much anticipated EZD 6 month result??)
Look forward to some explanation about data postponement at the AGM.

EDIT - the iii web address is continually struck off here so :

the usual iii address starting ...

followed by:

co.uk/articles/422115/four-aim-shares-post-election-world?context=LSE:SUMM

[freedosh] 23/6/2017 22:09

Excellent. Did anyone else get the feeling that Glyn would loved to have said "maybe preliminary approval after Phase ii if the results are sufficiently good"! ?Would likely require a post approval Phase iv confirmatory study of course.

[waterloo01] 22/6/2017 18:30

Unfortunately for the boys that are already immobile might be as good as it gets drug wise. Would be nice to think modulated utrophin might help/stop damage but unlikely to reverse it.

[freedosh] 22/6/2017 18:23

Raxone increases mitochondrial energy production and is also an anti oxidant
Therefore not a drug that will alter the natural history of the disease long term. More a temporary symptomatic benefit. Not a threat IMO

[waterloo01] 22/6/2017 18:14

Trying to take another run up at $11.50 on Nasdaq.

On at least one of the revised deadlines, we should have had the results by now. Oh well.

[football] 22/6/2017 18:08

Summit Therapeutics presents first data from reformulated DMD treatment
Share
15:46 22 Jun 2017

Summit wants to improve absorption of ezutromid in patients with duchenne muscular dystrophy (DMD) through a modified diet and new formulation.

Summit Therapeutics PLC (NASDAQ: SMMT LON:SUMM) has presented first clinical data for an upgraded version of ezutromid, its lead utrophin modulator, at the European Paediatric Neurology Society Congress in Lyon.

Summit wants to improve absorption of ezutromid in patients with duchenne muscular dystrophy (DMD) through a modified diet and new formulation.

"Our Phase 1 clinical development programme has identified ways to improve the pharmacokinetic profile of ezutromid.

Through both formulation development and dietary advice, ezutromid achieves exposures which we believe have the potential to sustain utrophin production in patients with DMD," said David Roblin, Summit’s president of R&D.

"We are now utilising both methods in our ongoing Phase 2 clinical trial, PhaseOut DMD, where we have the chance to see the impact of ezutromid drug exposure on pharmacology, safety and efficacy with longer term dosing of patients with DMD."

Duchenne Muscular Dystrophy, or DMD, is one of the most common, fatal genetic disorders diagnosed in children around the world.

It predominantly affects boys and it results in the progressive wasting of muscles throughout the body.

The disease has an estimated incidence of 1 in 5,000 and a patient population in the developed world of around 50,000. Patients typically don’t live beyond their late 20s.

It is caused by different genetic faults in the gene that encodes dystrophin, a protein that is essential for the healthy function of all muscles.

Utrophin protein is functionally and structurally similar to dystrophin and in preclinical studies the continued expression of utrophin had a meaningful, positive effect on muscle performance.

[waterloo01] 22/6/2017 16:41

Good to see the next generation up and running. Apart from finding out if the drug works...I'd really like to see what the next step re funding is for RDZ. The longer it goes on the more it leaves a feeling that whatever it is, a damp squib might come to mind. Hope not but it doesn't 'feel' like our hand has been bitten off with bidders/options.


US biotech on a tear with healthcare bill and good to see (below) UK authorities giving approval. If I recall it's a steroid and for use when boys are no longer mobile.

[solomon] 22/6/2017 16:21

Thanks, Freedosh. I kinda thought that was so, but the wording is ambiguous. If I had read to the next slide I should have been able to work it out.
The presentation does give a clearer indication that many assays are in progress. Summit would not want to give readings of MRI ad hoc, even though they are obtained non-invasively. Ad hoc would the impatient way to do things.

[freedosh] 22/6/2017 16:09

What they are hoping for solomon

[solomon] 22/6/2017 12:47

Slide 20
Potentially Positive Signals in PhaseOut DMD
Muscle Health
MRI Slowing or stabilization of fat fraction increase

Does this actually mean that the fat fraction has been shown to be stabilised? Or is that what they are hoping to find?

[chrisatrdg] 22/6/2017 12:28

RNS today:

Overcoming pharmacokinetic challenges to drug administration in DMD:
Lessons from Phase1 development of ezutromid

Bina Tejura MD

EPNS, Lyons, France, 22 June 2017

[chrisatrdg] 22/6/2017 11:36

Out today posted direct to Summit web site:

JMP Life Sciences Conference 21 June 2017

Developing Clinical Stage Programs to Treat DMD and CDI
Company Presentation June 2017



Edit: Many new slides not covered by 12.00 RNS today.

[waterloo01] 21/6/2017 11:40

At 3 events over next few days.

[football] 21/6/2017 10:53

Wasn't june supposed to be the time for lots of news and trade shows?